Toxicology of chlorofluorocarbon replacements. by Dekant, W
Toxicology ofChlorofiluorocarbon
Replacements
Wolfgang Dekant
Department ofToxicology, University ofWurzburg, Wurzburg, Germany
Chlorofluorocarbons (CFCs) are stable in the atmosphere and may reach the stratosphere. They
are cleaved by UV-radiation in the stratosphere to yield chlorine radicals, which are thought to
interfere with the catalytic cycle of ozone formation and destruction and deplete stratospheric
ozone concentrations. Due to potential adverse health effects of ozone depletion, chlorofluorocar-
bon replacements with much lower or absent ozone depleting potential are developed. The
toxicology of these compounds that represent chlorofluorohydrocarbons (HCFCs) or fluorohydro-
carbons (HFCs) has been intensively studied. All compounds investigated (1,1-dichloro-1-
fluoroethane [HCFC-141bl, 1,1,1,2-tetrafluoroethane [HFC-134a], pentafluoroethane [HFC-1251,
1-chloro-1,2,2,2-tetrafluoroethane [HCFC-1241, and 1,1-dichloro-2,2,2-trifluoroethane [HCFC-1231)
show only a low potential for skin and eye irritation. Chronic adverse effects on the liver (HCFC-
123) and the testes (HCFC-141b and HCFC-134a), including tumor formation, were observed in
long-term inhalation studies in rodents using very high concentrations of these CFC replace-
ments. All CFC replacements are, to varying extents, biotransformed in the organism, mainly by
cytochrome P450-catalyzed oxidation of C-H bonds. The formed acyl halides are hydrolyzed to
give excretable carboxylic acids; halogenated aldehydes that are formed may be further oxidized
to halogenated carboxylic acids or reduced to halogenated alcohols, which are excretory metabo-
lites in urine from rodents exposed experimentally to CFC replacements. The chronic toxicity of
the CFC replacements studied is unlikely to be of relevance for humans exposed during produc-
tion and application of CFC replacements. Environ Health Perspect 104(Suppl 1):75-83 (1996)
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Ozone, Chlorofluorocarbons,
and the Environment
Stratospheric ozone plays an important role
in reducing the amount ofultraviolet radia-
tion reaching the surface ofthe earth (1-3).
This protective shield in the stratosphere is
generated by the interaction of molecular
oxygen, UV-light, and particles. Ozone
is created by the reaction of an oxygen
atom, formed by photolytic dissociation of
molecular oxygen, with another molecule
of oxygen; this reaction is catalyzed by
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particles. Ozone itself is cleaved by photo-
lysis, and the formed oxygen atom recom-
bines with another oxygen molecule to
reform ozone. Ozone is removed by the
reaction with oxygen atoms under constant
conditions. The net result ofthese processes
is a dynamic steady state in which the rate
of formation of ozone is equal to the rate
ofozone degradation (4). This steady state
maybe disturbed by avariety offactors such
as solar radiation, meteorological effects,
and the concentrations ofchemically active
species such as NO and halogen radicals.
Halogen atoms such as chlorine catalyti-
cally reduce the steady-state concentration
of ozone. Reaction of ozone with a chlo-
rine radical forms chlorine monoxide and
molecular oxygen; chlorine monoxide
reacts with an oxygen atom thereby inter-
fering with the catalytic formation ofozone,
which results in a reduction ofstratospheric
ozone concentrations (Figure 1).
Among other natural sources of chlo-
rine such as vulcanic eruptions, chlorofluo-
rocarbons (CFCs) from anthropogenic
emissions have been implicated in the
observed reduction ofstratospheric ozone.
CFCs have been widely used since the
1930s because oftheir beneficial properties
for many industrial and household applica-
tions, e.g., in propellants, refrigeration, and
dry cleaning. CFCs are highly stable chem-
icals; thus, they are nonflammable, non-
toxic, and inexpensive; they are ideally
suited for refrigeration and metal degreas-
ing. Ironically, these beneficial properties
for commercial applications have made
CFCs troublesome for atmospheric chem-
istry. Due to their high volatility, a signifi-
cant amount of the produced CFCs was
released into the atmosphere; due to their
chemical inertness, CFCs are not degraded
in the troposphere and reach the stratos-
phere. Under the intensive UV-light in the
stratosphere, CFCs are photolytically
cleaved to yield chlorine radicals, which
then may participate in ozone destruction.
Besides participating in the destruction
ofstratospheric ozone, the release ofCFCs
may also contribute to global warming.
Several anthropogenic compounds includ-
ing CFCs influence the reflection of
infrared radiation from the surface of the
earth. Their increased release has been
associated with the observed increases in
average temperatures in the atmosphere.
Global warming potential (GWP) expresses
the increase in earthward infrared radiation
flux due to the emission ofa unit mass ofa
given compound and is expressed relative
to a reference compound, usually carbon
dioxide. CFCs are estimated to represent
approximately 20% of the man-made
greenhouse effect (5) (Table 1).
Due to the potential environmental
and health effects of ozone depletion,
e.g., increased incidences of skin cancer
and cataracts, the use of CFCs has been
reduced by international agreements.
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Figure 1. Mechanism of catalytic ozone destruction by
chlorine radicals formed from chlorofluorocarbons in
the stratosphere.
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Table 1. Estimated participation of different anthro-
pogenic gases to global warming.
Contribution
to global
Chemical Source warming, %
Carbon dioxide Energy generation, 50
traffic, heating
Chlorofluorocarbons Refrigeration, 20
foam blowing
Methane Agriculture 15
Tropospheric ozone Solar radiation, 7
locally increased
by anthropogenic
emissions
N20 Agriculture 5
Several developed countries have ceased the
production of CFCs and banned their
application; however, for many applica-
tions, CFCs are essential chemicals for
industrialized countries. Thus, replace-
ments for CFCs have to be developed (5).
Nonhalogenated compounds, due to their
flammability and other disadvantages, may
only substitute for part ofthe chlorofluoro-
carbon applications. Chlorofluorohydro-
carbons (HCFCs) and fluorohydrocarbons
(HFCs) have been developed as replace-
ments for CFCs. HCFCs will only be an
interim solution because they retain some
ozone-depleting potential and will be
phased out by the year 2020. However,
they are considered necessary as interim
replacements for CFCs due to problems in
adjusting several technologies to HFCs.
HCFCs and HFCs show many beneficial
properties ofCFCs, e.g., low flammability,
high volatility and suitability as refriger-
ants, but have a significantly lower poten-
tial for ozone depletion and global warming
(6). The much lower potential for ozone
depletion ofHCFCs is due to the presence
ofhydrogen atoms in the molecules, which
makes these compounds more readily
degradable by hydroxyl radicals in the
atmosphere, significantly reduces their
atmospheric lifetime, and prevents them
from reaching the stratosphere (7-9). Due
to the absence ofchlorine, hydrofluorocar-
bons are not expected to participate in
ozone depletion, but depending on the
content offluorine, they exhibit a GWP.
Their GWP depends on the number of
fluorine atoms in the molecule and
increases with higher fluorine substitution.
With respect to GWP, a compromise with
flammability has to be reached.
Due to the expected widespread appli-
cation of HCFCs and HFCs with the
potential ofhuman exposure at the work-
place and also in the general environment
(including the home), the toxicology of
these groups ofchemicals has been inten-
sively studied. Many ofthese studies were
performed by PAFT (Program ofAlternate
Fluorocarbon Toxicity Testing), a consor-
tium of chlorofluorocarbon producers.
Many ofthese studies have been published
or are available as reports. This review will
summarize the toxicology ofselected com-
pounds from the many potential CFC
replacements. The compounds listed in
Table 2 have been studied more intensively
and have already been introduced in the
market or are likely to be. In general, their
ozone depletion potential and their GWP
is significantly lower than those of CFCs
(Table 2).
Other compounds are also considered
for special applications such as 1,1,1,2,3,3,3-
heptafluoropropane (HFC-227) for the
generation of pharmaceutical aerosols;
however, the information on potential
toxic effects of these compounds is only
partially available and is therefore not
included here.
Toxicology of
Chlorofluorocarbons and
Chlorofluorocarbon
Replacements
Some general principles describing solvent
toxicology are also applicable to CFCs and
alternates. Although varying in chemical
structure and physicochemical properties,
most solvents produce a typical set oftoxic
effects upon acute administration ofhigh
doses (10). The most often induced effects
are dysfunction ofthe central nervous sys-
tem and, after sufficiently high exposure,
narcosis. These effects, observed after acute
exposure to most solvents, are based on the
distribution into lipid membranes due to
the lipid solubility of the solvents. The
effects are usually completely reversible if
the exposure is survived. The characteristic
effects of repeated solvent exposure are
irreversible toxic effects such as organ
necrosis or cancer. The magnitude ofthese
chronic toxic effects and the organs
affected are different between individual
solvents and depend on the rate and site of
solvent biotransformation to toxic metabo-
lites. The interaction ofthese metabolites
with cellular macromolecules may initiate
irreversible changes in cellular function
resulting in cell death or cancer.
Since most CFCs and their replace-
ments are lipophilic, upon exposure they
are rapidly taken up and distributed; narco-
sis is often the major toxic effect observed
after acute exposure. The lack of chronic
toxicity observed with CFCs is based on
their lack of biotransformation reactions.
The chronic toxic effects seen with CFC
replacements are probably based on the
ability ofexperimental animals, and pre-
sumably, humans, to metabolize these com-
pounds. The formed reactive intermediates
and their covalent binding to cellular con-
stituents or, more likely, the interference of
stable metabolites, which are formed with
homeostasis ofthe organism, are assumed
to be responsible for the chronic toxicity
observed with some CFCreplacements.
Toxicology of
Chlorofluorocarbons
No data on the environmental toxicology
of CFCs are available, but due to their
physiochemical properties, there is only a
low potential for toxicity and no bio-
accummulation is expected. The acute
toxic effects of trichlorofluoromethane
(CFC-1 1) and dichlorodifluoromethane
(CFC-12) in animals are restricted to nar-
cosis observed after inhalation of more
than 20,000 ppm resp. 200,000 ppm and
Table 2. Comparison of chlorofluorocarbon replacements to trichlorofluoromethane.
Estimated
atmospheric
Compound Intended use ODP GWP lifetime, years
Trichlorofluoromethane Refrigeration, blowing agent 1 1 144
1,1-Dichloro-1-fluoroethane Blowing agent, solvent 0.1 0.12 11
(HCFC-141b)
1,1,1,2-Tetrafluoroethane Refrigeration - 0.4 14
(HFC-134a)
Pentafluoroethane Refrigeration, fire extinguisher - 0.84 41
(HFC-125)
1-Chloro-1,2,2,2-tetra-fluoroethane Blowing agent, refrigeration 0.02 0.1 1.3
(HCFC-124)
1,1,1-Trifluoro-2,2-dichloroethane Refrigeration, blowing agent 0.02 0.02 1.6
(HCFC-123)
Abbreviations: ODP, ozone depletion potential; GWP, global warming potential.
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cardiac sensitization to catecholamines
after very high exposure concentrations.
No adverse effects except eye irritation and
slight neurotoxicity were seen in humans
exposed to very high concentrations
(>20,000 ppm CFC-1 1 and >40,000 ppm
for CFC-12) as volunteers or in laboratory
accidents and by application of CFCs as
propellants in pharmaceutical aerosols
(11). Both compounds are very weak irri-
tants and did not show teratogenic effects
in experimental animals. In subchronic and
chronic toxicity studies, both CFC-11 and
CFC-12 did not induce pathological
changes in any ofthe organs examined in
rats and they did not induce tumors in rats
and mice (12,13). No adverse effects were
observed in humans exposed for 4 weeks,
8hr/day to 1000 ppm ofCFC-11.
Both CFC-11 and CFC-12 are not
genotoxic in a variety of in vitro test sys-
tems. The lack ofchronic toxicity ofCFC-
11 and CFC-12 is most likely due to the
lack of biotransformation of these com-
pounds in the mammalian organism. CFCs
are rapidly taken up through the lung after
inhalation exposure; inhaled CFCs are
rapidly and quantitatively exhaled
unchanged in experimental animals and in
humans; metabolites formed were not
detected in urine. Moreover, 14CO2 was
not exhaled after inhalation of 14C-labeled
CFC-12 in humans (11). Only under the
specific conditions of very low oxygen
tension, metabolism ofCFC-11 to chloride
and CFC-12 was observed in liver micro-
somes ofrats. The relevance ofthis observa-
tion for the in vivo situation is questionable
because oxygen inhibited metabolite for-
mation; therefore, this pathway may be a
very minor contributor to the disposition
ofCFC-1 1.
ToxicologyofChlorofluorcarbon
Replacements
The Role ofBiotransformation Reactions
in the Toxicity ofCFC Replacements.
Parallel to the extensive toxicity studies
on CFC replacements, several groups
have been focusing on the metabolic
transformations of HCFCs and HFCs. In
principle, HCFCs and HFCs undergo
identical biotransformation reactions, as
has been elaborated for other halogenated
hydrocarbons (14-17).
Briefly, HCFCs and HFCs have been
shown to undergo cytochrome P450-
catalyzed oxidation reactions ofthe C-H a
bond or, in the absence ofoxygen, cyto-
chrome P450-catalyzed reduction reactions,
as demonstrated for some polyhalogenated
alkanes (18-20). The initial metabolites
formed by the cytochrome P450-catalyzed
oxidation reactions are geminal halohy-
drins, which may loose HX(X= Cl,F) to
form acyl halides or aldehydes. The acyl
halides thus formed are rapidly hydrolyzed
to give stable carboxylates, which are
excreted in urine as final metabolites. The
formed haloaldehydes may be excreted as
conjugates, oxidized to carboxylates, or
reduced to halogenated alcohols, which
are excreted as such or as sulfate or
glucuronide conjugates.
The cytochrome P450-catalyzed reduc-
tion ofHCFCs yields haloalkanes with one
halogen atom replaced by a hydrogen or
haloalkenes formed by the dehydrohalo-
genation ofhaloalkanes. Haloalkanes and
haloalkenes thus formed may also be oxi-
dized by cytochrome P450 to give halo-
genated aldehydes or carboxylic acids as
stable metabolites; fluoroalkenes may also
undergo conjugation with glutathione. The
formation of acyl halides represents a
bioactivation reaction for HCFCs and
HFCs because the formed intermediary
acyl halides are electrophiles and may react
with nucleophilic sites in macromolecules
as demonstarted for halothane and some
HCFCs (21,22). The reductive formation
ofhaloalkenes may also represent a bioacti-
vation reaction and contribute to HCFC
toxicity. Some fluoroalkenes such as
chlorotrifluoroethene are nephrotoxic;
their nephrotoxicity is based on their bio-
transformation by glutathione conjugation
followed by bioactivation of the derived
cysteine S-conjugates by cysteine conjugate
,B-lyase (23). In addition to short-lived
reactive intermediates, the formed stable
metabolites may also inititate toxic effects
of HCFs, especially under the conditions
ofchronic exposure. Under these condi-
tions, halogenated carboxylic acids, which
are only slowly eliminated due to a high
degree of plasma protein binding, may
accumulate to toxic concentrations. Some
halogenated carboxylic acids have been
shown to cause toxic effects. Trichloro-
acetic acid and dichloroacetic acid, for
example, cause liver toxicity and induced
hepatic carcinoma in rodents after long-
term administration in drinking water
(24-26). Repeated administration of
trifluoroacetic acid to rats caused hepato-
megalyand peroxisome proliferation in rats
(27). Dichloroacetic acid and bromo- and
dibromoacetate are testicular toxins
(28,29). Moreover, some fluorinated alde-
hydes and alcohols are toxic in animals or
show toxic effects in vitro. For example,
chlorodifluoroacetaldehyde inhibits esterases
in vitroand trifluoroethanol causes intestinal
toxicity in rodents (30,31).
Uptake, Biotransformation, and
Elimination of Chlorofluorocarbon
Replacements in Mammals. Studies on
the biotransformation of CFC replace-
ments have been performed in vitro in rat
liver subcellular fractions and in human
liver microsomes and in rats in vivo.
Cytochrome P450 enzymes have been
shown to catalyze the enzymatic oxidation
of the C-H bond in CFC replacements.
The cytochrome P450 enzyme 2E1 has
been demonstrated to play an important
role in the oxidation of CFC replace-
ments. This enzyme is present in rat and
human liver and in rat kidney; its concen-
tration in the liver is influenced by a vari-
ety of inducers such as organic solvents
and ethanol but also by dietary factors and
some drugs. The concentrations of this
enzyme in human liver samples varies
approximately 5-fold; therefore, differ-
ences in the extent of the biotransforma-
tion ofCFC replacements can be expected
between individuals (32-34).
In pyridine-induced rat liver micro-
somes, 1,1-dichloro-1 -fluoroethane
(HCFC-141b) is oxidized to 2,2-dichloro-
2-fluoroethanol. In rats, HCFC-141b is
rapidly absorbed after inhalation and
undergoes a saturable uptake in the rat. In
rats exposed by inhalation in a closed
chamber to varying concentrations of
HCFC-141b, low concentrations of the
glucuronide of 2,2-dichloro-2-fluoro-
ethanol were found as a metabolite in urine
after 11,400 ppm. A linear relationship
between HCFC-141b exposure concentra-
tions and the urinary excretion of 2,2,-
dichloro-2-fluoroethanol was observed.
After exposure of rats to 40,000 ppm
HCFC-141b, dichlorofluoroacetic acid was
also found as a metabolite in urine (Figure
2). Overall, the level ofbiotransformation
ofHCFC-141b in rats is low (35-37).
The biotransformation of 1,1,1,2-
tetrafluoroethane (HFC-134a) has been
studied in rat liver microsomes, freshly
isolated rat hepatocytes, in human hepato-
cytes, and in rats in vivo. In rat and human
liver microsomes, HFC-134a undergoes
limited cytochrome P450 2E1 metabolism
to inorganic fluoride (38,39). The extent
ofbiotransformation ofHFC-134a in rats
is also low. In studies with male and female
Wistar rats exposed once to 10,000 ppm
14C-labeled HFC-134a, total radioactivity
present in expired air, urine, and feces
amounted to approximately 1% of the
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Figure 2. Metabolic pathway of HCFC-141b in rats. Dichlorofluoroacetic acid was only formed after exposure to
very high concentrations (Glu = glucuronide).
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Figure 3. Biotransformation of HCFC-134a in rodents.
inhaled dose in both sexes. More than 60%
of the inhaled dose was recovered within
1 hr after cessation of exposure as
unchanged HFC-134a; the remaining
radioactivity was excreted as carbon diox-
ide in exhaled air, as trifluoroacetic acid in
urine, and as unidentified metabolites in
feces (Figure 3) (40).
Pentafluoroethane (HFC-125) is
metabolized very slowly in the rat in vivo.
The major urinary metabolite has been
identified as trifluoroacetic acid; the con-
centrations ofthis metabolite in the urine
of rats comparatively exposed to identical
concentrations of HFC-125, 1-chloro-
1,2,2,2-tetrafluoroethane (HCFC-124),
and 1,1-dichloro-2,2,2-trifluoroethane
(HCFC-123) were lowest in HFC-125-
treated rats. Concentrations oftrifluoro-
acetic acid in urine were 10-fold higher in
rats exposed to HCFC-124 and 40- to
50-fold higher in rats exposed to HCFC-
123. These differences correlate well with
differences seen in the extent ofbiotrans-
formation ofthese three CFC replacements
in rat liver microsomes, with the extent of
hepatic protein trifluoroacetylation, and
with the predicted enthalpies of activation
for hydrogen atom abstraction within this
series ofcompounds (41).
Limited metabolic data have been pub-
lished on the bioactivation of HCFC-124.
Olson et al. (39) exposed rats to 10,000
ppm HCFC-124 for 2 hr and found both
inorganic fluoride and trifluoroacetic acid,
both products ofan oxidative metabolism,
in their urine. Increases in urinary fluoride
levels in rats exposed by subchronic inhala-
tion to HCFC-124 have also been reported
(Figure 4).
The metabolism of HCFC-123 has
been studied more intensively than that
of other CFC replacements. The results
suggest that HCFC-123 biotransformation
is very similar to that of the anestetic
halothane. As seen with halothane, tri-
fluoroacetic acid is the major product
of HCFC-123, both in rat and human
liver microsomes and in rats in vivo. Figure
5 shows the pathways of HCFC-123
biotransformation in rodents (42-44).
Both halothane and HCFC-123 are
biotransformed to trifluoroacetic acid,
which has long been known as a major
halothane metabolite (45,46). The
identification of trifluoroacetic acid as a
major microsomal metabolite of HCFC-
123 demonstrates that an identical reaction
occurs with HCFC-123. Trifluoroacetate is
formed by the oxidation of the carbon-
hydrogen bond in HCFC-123 followed by
the loss of hydrochloric acid to give
trifluoroacetyl chloride. This reactive acy-
lating agent may bind to proteins. Indeed,
studies on the in vivo metabolism and
covalent binding of HCFC-123 using
immunoblotting with a hapten-specific
antitrifluoroacetyl protein serum and 19F-
NMR spectra identified Nr-trifluoroacety-
lated lysine residues in proteins (21).
However, studies on the microsomal
metabolism also showed differences in the
structures of metabolites formed from
halothane and HCFC-123. Chlorodi-
fluoroacetic acid is a metabolite formed
from HCFC-123 but not from halothane.
The mechanism for the enzymatic forma-
tion ofchlorodifluoroacetetate is unclear;
however, experimental evidence points to
1,1-dichloro-2,2-difluoroethene as an
intermediate metabolite of HCFC-123.
Chlorodifluoroacetate may be formed
from HCFC-123 by a cytochrome P450-
mediated oxidation of this potential
metabolite. Cytochrome P450 has been
shown to oxidize alkanes to olefins (47).
Oxidation of this olefin by cytochrome
P450 proceeds under rearrangement and
gives chlorodifluoroacetate (48).
1,1-Dichloro-2,2-difluoroethene is also
a likely intermediate metabolite of HCFC-
123 formed in vivo in rats. After exposure
to HCFC-123, a conjugation reaction of
1,1-dichloro-2,2-difluoroethene with glu-
tathione (42,44) forms an S-conjugate,
which is processed by the enzymes ofmer-
capturic acid formation (49) to form uri-
nary mercapturic acid, N-acetyl-S-(2,2-
dichloro-1,1-difluoroethyl)-L-cysteine.
This urinary mercapturic acid has been
identified in the urine of rats and guinea
pigs after exposure to low concentrations
ofHCFC-123.
[ OH 1
F3CCHFX)P450
- H F3C-CHF(X) > F3C-C-F | F3C C\
L xJ F
+ H20
- HF
F3C C\
OH
Figure 4. Biotransformation of HCFC-124 (X=Cl) and HCFC-125 (X=F) in rodents.
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Figure 5. Metabolic pathways of HCFC-123 in rats in vivo and in rat liver microsomes. Metabolites identified
[trifluoroacetic acid, N-trifluoroacetyl-2-aminoethanol, and N-acetyl-S-(1,1-dichloro-2,2-difluoro)-L-cysteineI are
underlined.
Because the microsomal incubations
did not contain glutathione, this metabo-
lite was not observed in vitro. Instead,
oxidation by cytochrome P450 to chloro-
fluoroacetic acid occurred. Cytochrome
P450-catalyzed oxidation in vivo seems to
occur only after 1,1-dichloro-2,2-difluoro-
ethene doses that saturate the capacity of
the glutathione S-transferases responsible
for 1,1-dichloro-2,2-difluoroethene conju-
gation (48). Under reduced oxygen ten-
sion, reduction of HCFC-123 to give
1-chloro-2,2,-trifluoroethane and 1-chloro-
2,2-difluoroethene has also been observed
in low yields in rat liver microsomes (50)
but not in rats in vivo.
Acute and Subchronic Toxicity of
Chlorofluorocarbon Replacements. The
acute toxicity of CFC replacements by
inhalation or oral administration is low.
The 15-min LC50 values are usually above
500,000 ppm, and toxic effects consist of
impairment of coordination of response
reactions to external stimuli and other
signs ofdepression ofthe central nervous
system. Moreover, CFC replacements have
a low potential for skin and eye irritation.
Similar to other halogenated hydrocarbons,
high concentrations ofsome CFC replace-
ments cause the mammalian heart to react
abnormally to adrenaline, which results in
cardiac arrythmias. For example, such toxic
effects are seen after exposure of Beagle
dogs to 100,000 ppm of HFC-134a and
5,000 ppm ofHCFC-141b (37,51).
Studies describing the subchronic toxic-
ity of CFC replacements are available for
HCFC-141b, HFC-134a, HFC-125,
HCFC-124, and HCFC-123 (52-56). In
a 13-week inhalation study, Fischer 344
rats were exposed 6 hr/day, 5 days/week to
HCFC-141b concentrations up to 20,000
ppm. Signs of central nervous system
depression were observed after inhalation
ofthe highest concentration. After both 4
and 13 weeks ofexposure, plasma concen-
trations of cholesterol, triglycerides, and
glucose were slightly raised in the rats
exposed to 20,000 ppm. There were no
changes in hematological or histopatho-
logical findings that could be attributed to
exposure to dichlorofluoroethane.
The potential for subchronic toxicity of
HFC-134a is also low. Rats were exposed
for 13 weeks to concentrations up to 50,000
ppm HFC-134a (6 hr/day, 5 days/week).
Ten males and 10 females from each group
were killed in week 14 following their last
exposure, and the remaining animals were
killed in week 18 following a 4-week recov-
ery phase. Small differences in body-weight
gain and food consumption were noted
between treated and control animals,
which were not considered to be related
to the exposure to HFC-134a. There were
no significant differences in blood or
urine clinical chemistry parameters, hema-
tology parameters, or organ weights and no
treatment-related macroscopic or micro-
scopic findings (5741).
Four groups of20 male and 20 female
Sprague-Dawley rats were exposed to
HFC-125 (6 hr/day, 5 days/week) for 4
consecutive weeks at concentrations up to
15,000 ppm. Ten rats per sex at each con-
centration level were kept untreated for 4
weeks after the end of exposure. No mor-
tality occurred; there were no compound-
related effects on body weight, clinical
signs, hematology, biochemistry, urin-
analysis, organ weight, and tissue morphol-
ogy. No increases in plasma and urinary
fluoride concentrations were seen. Levels of
peroxisomal P-oxidation activity of the
liver were comparable to controls at all
exposure concentrations (62).
In a 90-day inhalation toxicity study
(63), both sexes of rats and mice were
exposed to HCFC-124 for 6 hr/day and
5 days/week at concentrations up to
50,000 ppm. There were no compound-
related effects on mortality, body weight,
food consumption, clinical signs, hematol-
ogy, organ weight, or tissue morphology
at any exposure concentrations. During
exposure to 50,000 ppm, rats were less
responsive to stimuli compared to control
rats. Relative to blood chemistry measure-
ments, at a 45-day clinical evaluation
interval, male rats and mice exposed to
15,000 or 50,000 ppm HCFC-124 had
lower serum triglyceride concentrations
than controls; female rats at 50,000 ppm
showed increased alkaline phosphatase
activity. At all exposure levels, fluoride
concentrations in blood and urine were ele-
vated. The mild diuresis observed at several
sampling intervals in rats was considered a
result of increased osmotic activity from
the excreted fluoride ions rather than a
direct effect ofthe compound.
The subchronic toxicity of HCFC-123
has been evaluated in four inhalation toxic-
ity studies from 1 to 3 months in duration
with exposure levels ranging from 300 to
20,000 ppm. Three ofthe studies used rats
only; one study used both rats and dogs.
Increases in relative liver weights were seen
after inhalation of 1,000 ppm and higher
HCFC-123; except for the 90-day expo-
sure, minimal histopathological changes
were noted. Clinical chemistry and bio-
chemical investigations showed induction
ofperoxisomal ,-oxidation, a decrease in
serum cholesterol and triglyceride levels, and
increased urinary fluoride levels (5840).
Chronic Toxicity and Tumorigenicity
ofChlorofluorocarbon Replacements.
Chronic toxicity and carcinogenicity bioas-
says have been reported for HCFC-141b,
HFC-134a, and HCFC-123 (61,64,65).
Sprague-Dawley rats were exposed
(whole body) by inhalation 6 hr/day, 5
days/week for 104 weeks to concentrations
up to 15,000 ppm HCFC-141b. The
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highest exposure level was increased to
20,000 ppm after 17 weeks ofexposure, in
light ofthe absence ofany toxicity signs up
to this point. The survival rate in the
exposed groups did not differ from those in
the control groups, and no clinical signs of
toxicity could be associated with exposure
to HCFC-141b. There was a slight but sta-
tistically significant reduction in body-
weight gain and food consumption in the
high-dose group, particularly in the males.
There were no intergroup differences in
the incidence ofocular abnormalities or in
any ofthe hematological parameters. There
were no blood and urinary biochemical
effects, although occasional decreases in
serum triglycerides in high-dose group rats
may have been related to treatment. Organ-
weight effects were also not changed by
exposure to HCFC-141b. There were no
intergroup differences with respect to
macroscopic and microscopic examinations
at 52 weeks. After 104 weeks increased tes-
ticular weights in the highest exposure
group were seen. Histological examinations
did not show any treatment-related effects
except a small increase in the number of
vacuolated sinusoidal histiocytes ofthe cer-
vical lymph nodes in the high-concentra-
tion group and a statistically significant
increase ofthe incidence ofhyperplasia and
benign tumors ofthe testicular interstitial
cells (Leydig cells) in the medium- and
high-concentration groups (61).
Toxic effects on the testes were also
observed in rats exposed to HFC-134a [by
gavage of 300 mg/kg body weight (bw)
HFC-134a in corn oil, 5 days/week for 52
weeks]. After 125 weeks in this study,
HFC-134a did not increase the incidence
of tumors in any of the organs from the
treated group when compared with the
control groups (13).
A combined chronic toxicity/carcino-
genicity study was conducted by whole
body inhalation exposures with concentra-
tions up to 50,000 ppm HFC-134a for 6
hr/day, 5 days/week. All groups had a simi-
lar survival rate. The differences in body
weight and food consumption reflected only
biological variation and were not compound
related. There was no evidence oftoxicity
effects at any exposure level in the clinical
chemistry and hematology parameters inves-
tigated. The only treatment-related effect of
toxicological significance was confined to
the testes of male rats exposed to 50,000
ppm. There was a statistically significant
increase inweight ofthe testes over controls
and an increased incidence ofLeydig cell
hyperplasia and benign Leydig cell tumors.
In a chronic toxicity/carcinogenicity
study, male and female rats were exposed
to concentrations of up to 5,000 ppm
HCFC-123 for 24 months. The exposed
rats showed an increased survival rate and a
decreased incidence of a variety of age-
related lesions. In addition, dosed animals
had decreased serum triglyceride and glu-
cose concentrations, lower body weights,
and lower body-weight gains. At the end of
the study, increased incidences ofhepato-
cellular adenomas were seen in the high-
dose males and in females exposed to 300,
1,000, and 5,000 ppm. Hepatic cholan-
giofibromas were also observed in females
in the highest dose group, and increased
incidences of pancreatic acinar cell carci-
noma were seen at all doses in males. In
addition, the incidence oftesticular inter-
stitial adenomas was increased in all groups
ofdosed males.
Genetie Toxicology ofChlorofluoro-
carbon Replacements. The mutagenic
properties of CFC replacements were
investigated in bacterial assays, chromoso-
mal abberation assays in cultured mam-
malian cells in vitro, and in in vivo
micronucleus assays. In most studies with
pure CFC replacements, negative responses
were obtained, both in Salmonella typhi-
murium and in Escherichia coli. Moreover,
CFC replacements did not show evidence
ofclastogenic activity in cultured Chinese
hamster ovary cells or in human lympho-
cytes with and without metabolic activa-
tion by rat liver S-9. In vivo, the majority
of tests for clastogenic activity did not
indicate an effect ofexposure to high CFC
replacement concentrations. In summary,
the data ofthe mutagenicity studies suggest
that CFC replacements do not have
mutagenic properties (53-56).
Reproductive Effeets and Terato-
geniciy ofCFCReplacements. There was
no evidence ofteratogenic or embryotoxic
effects in pregnant rabbits exposed to con-
centrations up to 12,600 ppm or in preg-
nant rats exposed to 3,200 or 7,900 ppm
of HCFC-141b, although signs of mater-
nal toxicity were observed at the higher
dose in rats and above 4,200 ppm in rab-
bits. A two-generation inhalation study in
rats demonstrated a no-observed effect
level of 8,000 ppm for reproductive para-
meters (66). At a higher concentration,
20,000 ppm, a nonreproducible decrease
was observed in the number oflitters and
the number of pups per litter; there was
also some retardation ofsexual maturation
ofmale pups that may have been caused by
the slight body-weight growth retardation.
HFC-134a showed no adverse effects on
fertility in a limited study in mice. It was
not teratogenic in rats and rabbits. Only
nonspecific effects on fetal maturation in
the form ofdelayed ossification in the rat
were observed at 50,000 ppm and above.
Developmental toxicity studies with
HCFC-125 by inhalation were carried out
both in rats and rabbits. No evidence of
embryotoxicity or teratogenicity was seen,
even at exposure levels as high as 50,000
ppm. No evidence of embryotoxicity or
teratogenicity of HCFC-124 was seen in
developmental studies by inhalation in rats
and rabbits at exposure levels as high as
50,000 ppm. Minimal evidence of mater-
nal toxicity was seen at concentrations of
15,000 ppm and above in each of these
studies. When pregnant rats and rabbits
were exposed to HCFC-123 at very high
concentrations during a critical part of
their gestation, there was no evidence of
teratogenicity or embryotoxicity and
evidence ofonly slight maternal toxicity.
Relevance ofTumorigenic Effects of
Chlorofluorocarbon Replacements in
Animalsfor Human Risk Assessment.
Due to low acute and subchronic toxicity
of CFC replacements, the toxic effect of
concern for human risk assessment is the
tumorigenicity observed in rodents after
long-term inhalation ofhigh concentra-
tions of CFC replacements. Benign testi-
cular tumors were observed after inhalation
ofHCFC-141b, HFC-134a, and HCFC-
123. In addition, HCFC-123 caused
hepatic and pancreatic tumors. Because a
variety of in vitro and in vivo test systems
have not demonstrated genotoxic activity
of these CFC replacements, tumor initia-
tion is probably caused by nongenotoxic
mechanisms.
Benign tumors ofthe testicular intersti-
tial cells (Leydig cell adenoma) are com-
mon in the aging rat. Benign Leydig cell
tumors appear late in life and are not life
threatening to rats. They are associated
with the senescence process. The sponta-
neous incidence ofthis tumor type varies
from one strain to another, ranging from a
few percent in Sprague-Dawley rats up to
100% in some Wistar-derived and in
Fischer 344 rats (67). These tumors do not
usually progress to malignancy in the rat
(e.g., no malignant Leydig cell tumors were
found in several thousand control Fischer
rats) (68,69). Leydig cells secrete sex hor-
mones (e.g., testosterone, dihydroandos-
terone, estradiol). The high incidence of
hyperplasia and tumors of these testicular
cells in old rats may be related to senile
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endocrine disturbance (70). Leydig cell
tumors in the rat are induced by a variety
of different chemical structures. Their
formation is associated with hormonal
imbalances, especially imbalances ofsex hor-
mones, and is also observed after treatment
with estrogens. It is therefore assumed that
HCFC-141b and HFC-134a exaggerate
hormonal disturbances linked with senility
resulting in Leydig cell hyperplasia and
tumor formation. The role of parent
HCFC or of metabolites formed by bio-
transformation in the testicular toxicity is
not defined. However, fluorinated aldehy-
des such as trifluoroacetaldehyde are testic-
ular toxins; their formation may contribute
to the observed toxic effects (71).
The pathways of HCFC-123 metabo-'
lism and the lack of genotoxicity of
HCFC-123 and the identified metabolites
suggest that nongenotoxic effects are most
likely responsible for the tumor induction
observed after long-term inhalation of
HCFC-123. Moreover, the lack ofcova-
lent binding of HCFC-123 in testes and
pancreas (42), two target organs ofHCFC-
123 tumorigenicity, and the lack of
detectable cytochrome P450 2E1-expres-
sion in these organs indicate that metabolic
activation reactions do not play a role in
HCFC-123 toxicity to these organs.
However, the mechanisms responsible for
the tumor induction by HCFC-123 are
unclear. HCFC-123 and its major metabo-
lite, trifluoroacetic acid, induce hepato-
megaly; HCFC-123 also induced an
increase in hepatic beta-oxidation, a
marker for hepatic peroxisome prolifera-
tion. Peroxisome proliferation has been
demonstrated to be causally linked to the
induction of liver tumors in rodents by
nongenotoxic, receptor-mediated mecha-
nisms involving cell proliferation (72-74);
however, an increased cell proliferation in
the liver could not be demonstrated after
12 months ofHCFC-123 exposure in rats.
Moreover, the relationship between the
disturbances in lipid metabolism, peroxi-
some proliferation, and hepatic tumor
induction is unclear. The induction of
testicular interstitial cell-adenomas by
HCFC-123 may also be related to hepatic
peroxisome proliferation. Perfluorooctano-
ate, a perfluorinated carboxylic acid, that is
structurally related to trifluoroacetic acid
(the major metabolite ofHCFC-123), also
causes testicular adenomas, probably by
induction ofhormonal imbalances (75).
The minor HCFC-123 metabolite 1-
chloro-2,2,2-trifluoroethane (76) is a tes-
ticular toxin; its testicular toxicity likely is
based on its biotransformation to trifluoro-
acetaldehyde (77). The formation of this
metabolite could also contribute to toxic
effects on the testes after long-term admin-
istration. Peroxisome proliferation or dis-
turbances oflipid metabolism may also be
causative factors in the induction ofpan-
creatic tumors by HCFC-123; however, a
more in-depth understanding ofthe issues
needs to be developed.
Environmental Toxicology of
Chlorofluorocarbon Replacements. Most
CFC replacements have been only partly
tested for toxic effects on organisms in the
environment. HCFC-141b, HFC-134a,
and HCFC-123 have only a low acute
toxicity to aquatic organisms. The low
octanol/water coefficients of these com-
pounds and their high volatility make
bioaccumulations very unlikely. Based on
the anticipated production volumes and
the mechanisms of atmospheric degrada-
tion, the contribution of released fluoride
from these compounds to total atmos-
pheric flux is calculated to be very low. The
formation ofhydrochloric and hydrofluoric
acid from HCFC replacements and their
collection in rainwater is also expected to
represent only a very minor contribution to
the generation ofacid rain. At the antici-
pated production volumes and the
amounts expected to be released, trifluoro-
acetic acid formed by atmospheric degrada-
tion of HCFC-123, HCFC-124, and
HCFC-125 also will contribute only in a
very minorway to acid rain (78).
Conclusions
Due to anticipated widespread use ofCFC
replacements, there has been a major effort
to characterize their direct toxic effects on
humans and their effects on the environ-
ment. The selected CFC replacements
are characterized by a low potential for
acute and chronic toxicity and can be
handled safely, with a much-reduced
environmental impact compared to CFCs.
The chronic toxic and tumorigenic effects
observed with selected CFC replacements
are not likely to be ofrelevance for human
risk assessment ofCFC-replacement expo-
sure during production and application.
Based on the available data and the lack of
genotoxicity of CFC replacements, the
observed effects, with the exception of
HCFC-123, likely occur only after appli-
cation ofvery high doses not expected to
be encountered by humans. Further
research is required for a better under-
standing ofthe chronic toxicity ofHCFC-
123 and the mechanisms involved.
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